Portola Pharmaceuticals
Pharmaceuticals, 270 E Grand Ave, South San Francisco, California, 94080, United States, 201-500 Employees
Phone Number: +13*********
Who is PORTOLA PHARMACEUTICALS
We are focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Co...
Read More
-
Headquarters: 270 E Grand Ave, South San Francisco, California, 94080, United States
-
Date Founded: 2003
-
Employees: 201-500
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from PORTOLA PHARMACEUTICALS
Portola Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Portola Pharmaceuticals
Answer: Portola Pharmaceuticals's headquarters are located at 270 E Grand Ave, South San Francisco, California, 94080, United States
Answer: Portola Pharmaceuticals's phone number is +13*********
Answer: Portola Pharmaceuticals's official website is https://portola.com
Answer: Portola Pharmaceuticals's revenue is $100 Million to $250 Million
Answer: Portola Pharmaceuticals's SIC: 2834
Answer: Portola Pharmaceuticals's NAICS: 325412
Answer: Portola Pharmaceuticals has 201-500 employees
Answer: Portola Pharmaceuticals is in Pharmaceuticals
Answer: Portola Pharmaceuticals contact info: Phone number: +13********* Website: https://portola.com
Answer: We are focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya (andexanet alfa), and Bevyxxa (betrixaban). The company also is advancing cerdulatinib, an investigational SYK/JAK inhibitor being developed for the treatment of hematologic cancers. We are continuing to explore new discoveries that impact how serious blood-related disorders are treated and expanding the potential impact of our existing portfolio of medicines.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month